Zompi S, Legrand O, Bouscary D, Blanc C M, Picard F, Casadevall N, Dreyfus F, Marie J P, Viguié F
Services d'Hématologie biologique et clinique, Hôpital Hôtel-Dieu, and Services d'Hématologie biologique et clinique, Hôpital Cochin, Paris, France.
Br J Haematol. 2000 Sep;110(3):610-3. doi: 10.1046/j.1365-2141.2000.02240.x.
We describe two patients with positive t(15;17) acute promyelocytic leukaemia (APL) that developed into a therapy-related myelodysplasia 2-2.5 years after complete remission (CR) and then evolved into therapy-related acute myeloid leukaemia (t-AML). Both patients received anthracyclines as potential leukaemogenic drugs. In both cases, cytogenetic changes usually occurring after use of alkylating agents were noticed: monosomy 7 associated with monosomy 5 or 5q- chromosome. A review of the literature on t-AML occurring after successful therapy for APL showed only one report similar to these two cases. These observations suggest that anthracyclines can cause t-AML similar to that induced by alkylating agents.
我们描述了两名患有t(15;17)阳性急性早幼粒细胞白血病（APL）的患者，他们在完全缓解（CR）后2至2.5年发展为治疗相关的骨髓增生异常综合征，随后演变为治疗相关的急性髓系白血病（t-AML）。两名患者均接受了蒽环类药物作为潜在的致白血病药物。在这两个病例中，均发现了通常在使用烷化剂后出现的细胞遗传学改变：与5号染色体单体或5q-染色体相关的7号染色体单体。对APL成功治疗后发生的t-AML的文献综述显示，仅有一篇报告与这两个病例相似。这些观察结果表明，蒽环类药物可导致与烷化剂诱导的t-AML相似的疾病。
